Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients.

Detalles Bibliográficos
Autores:	Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2024
País:	España
Institución:	Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:	oai:i3pt.fundanetsuite.com:p4328
Acceso en línea:	https://i3pt.portalinvestigacion.com/publicaciones/4328 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181761067&doi=10.1158%2f1078-0432.CCR-23-0771&partnerID=40&md5=a4ac2303bc43a6a87bd90d23c549a28a
Access Level:	acceso abierto
Palabra clave:	Bevacizumab Carcinoma, Ovarian Epithelial Chemotherapy, Adjuvant Female Forkhead Transcription Factors Humans Neoadjuvant Therapy Ovarian Neoplasms Tumor Microenvironment bevacizumab carboplatin paclitaxel transcription factor FOXP3 forkhead transcription factor advanced cancer Article cancer resistance cancer survival CD4+ T lymphocyte CD8+ T lymphocyte cell subpopulation clinical article clinical outcome controlled study cytoreductive surgery female human human cell human tissue immunofluorescence immunohistochemistry multiple cycle treatment neoadjuvant chemotherapy ovary cancer progression free survival regulatory T lymphocyte tumor microenvironment tumor-associated macrophage adjuvant chemotherapy neoadjuvant therapy ovary carcinoma ovary tumor pathology procedures

id	ES_98b8221dd6441587c2a16a4e5dfa03c8
oai_identifier_str	oai:i3pt.fundanetsuite.com:p4328
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).Tavira BIscar TManso LSantaballa AGil-Martin MGarcía García YRomeo MIglesias Mde Juan Ferré ABarretina-Ginesta MPManzano AGaba LRubio MJde Andrea CEGonzález-Martín ABevacizumabCarcinoma, Ovarian EpithelialChemotherapy, AdjuvantFemaleForkhead Transcription FactorsHumansNeoadjuvant TherapyOvarian NeoplasmsTumor Microenvironmentbevacizumabcarboplatinpaclitaxeltranscription factor FOXP3bevacizumabforkhead transcription factoradvanced cancerArticlecancer resistancecancer survivalCD4+ T lymphocyteCD8+ T lymphocytecell subpopulationclinical articleclinical outcomecontrolled studycytoreductive surgeryfemalehumanhuman cellhuman tissueimmunofluorescenceimmunohistochemistrymultiple cycle treatmentneoadjuvant chemotherapyovary cancerprogression free survivalregulatory T lymphocytetumor microenvironmenttumor-associated macrophageadjuvant chemotherapyneoadjuvant therapyovary carcinomaovary tumorpathologyprocedurestumor microenvironmentThe aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients.AMER ASSOC CANCER RESEARCH2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/4328https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181761067&doi=10.1158%2f1078-0432.CCR-23-0771&partnerID=40&md5=a4ac2303bc43a6a87bd90d23c549a28aCLINICAL CANCER RESEARCHISSN: 10780432ISSNe: 15573265reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p43282026-06-21T15:30:37Z
dc.title.none.fl_str_mv	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
title	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
spellingShingle	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study). Tavira B Bevacizumab Carcinoma, Ovarian Epithelial Chemotherapy, Adjuvant Female Forkhead Transcription Factors Humans Neoadjuvant Therapy Ovarian Neoplasms Tumor Microenvironment bevacizumab carboplatin paclitaxel transcription factor FOXP3 bevacizumab forkhead transcription factor advanced cancer Article cancer resistance cancer survival CD4+ T lymphocyte CD8+ T lymphocyte cell subpopulation clinical article clinical outcome controlled study cytoreductive surgery female human human cell human tissue immunofluorescence immunohistochemistry multiple cycle treatment neoadjuvant chemotherapy ovary cancer progression free survival regulatory T lymphocyte tumor microenvironment tumor-associated macrophage adjuvant chemotherapy neoadjuvant therapy ovary carcinoma ovary tumor pathology procedures tumor microenvironment
title_short	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
title_full	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
title_fullStr	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
title_full_unstemmed	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
title_sort	Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
dc.creator.none.fl_str_mv	Tavira B Iscar T Manso L Santaballa A Gil-Martin M García García Y Romeo M Iglesias M de Juan Ferré A Barretina-Ginesta MP Manzano A Gaba L Rubio MJ de Andrea CE González-Martín A
author	Tavira B
author_facet	Tavira B Iscar T Manso L Santaballa A Gil-Martin M García García Y Romeo M Iglesias M de Juan Ferré A Barretina-Ginesta MP Manzano A Gaba L Rubio MJ de Andrea CE González-Martín A
author_role	author
author2	Iscar T Manso L Santaballa A Gil-Martin M García García Y Romeo M Iglesias M de Juan Ferré A Barretina-Ginesta MP Manzano A Gaba L Rubio MJ de Andrea CE González-Martín A
author2_role	author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Bevacizumab Carcinoma, Ovarian Epithelial Chemotherapy, Adjuvant Female Forkhead Transcription Factors Humans Neoadjuvant Therapy Ovarian Neoplasms Tumor Microenvironment bevacizumab carboplatin paclitaxel transcription factor FOXP3 bevacizumab forkhead transcription factor advanced cancer Article cancer resistance cancer survival CD4+ T lymphocyte CD8+ T lymphocyte cell subpopulation clinical article clinical outcome controlled study cytoreductive surgery female human human cell human tissue immunofluorescence immunohistochemistry multiple cycle treatment neoadjuvant chemotherapy ovary cancer progression free survival regulatory T lymphocyte tumor microenvironment tumor-associated macrophage adjuvant chemotherapy neoadjuvant therapy ovary carcinoma ovary tumor pathology procedures tumor microenvironment
topic	Bevacizumab Carcinoma, Ovarian Epithelial Chemotherapy, Adjuvant Female Forkhead Transcription Factors Humans Neoadjuvant Therapy Ovarian Neoplasms Tumor Microenvironment bevacizumab carboplatin paclitaxel transcription factor FOXP3 bevacizumab forkhead transcription factor advanced cancer Article cancer resistance cancer survival CD4+ T lymphocyte CD8+ T lymphocyte cell subpopulation clinical article clinical outcome controlled study cytoreductive surgery female human human cell human tissue immunofluorescence immunohistochemistry multiple cycle treatment neoadjuvant chemotherapy ovary cancer progression free survival regulatory T lymphocyte tumor microenvironment tumor-associated macrophage adjuvant chemotherapy neoadjuvant therapy ovary carcinoma ovary tumor pathology procedures tumor microenvironment
description	The aim of our study was to elucidate the impact of bevacizumab added to neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment and correlate the changes with the clinical outcome of the patients.
publishDate	2024
dc.date.none.fl_str_mv	2024
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://i3pt.portalinvestigacion.com/publicaciones/4328 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181761067&doi=10.1158%2f1078-0432.CCR-23-0771&partnerID=40&md5=a4ac2303bc43a6a87bd90d23c549a28a
url	https://i3pt.portalinvestigacion.com/publicaciones/4328 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181761067&doi=10.1158%2f1078-0432.CCR-23-0771&partnerID=40&md5=a4ac2303bc43a6a87bd90d23c549a28a
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	AMER ASSOC CANCER RESEARCH
publisher.none.fl_str_mv	AMER ASSOC CANCER RESEARCH
dc.source.none.fl_str_mv	CLINICAL CANCER RESEARCH ISSN: 10780432 ISSNe: 15573265 reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str	Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection	r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869414216054603776
score	15.812429

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

Similares en LA Referencia